Platforms
Platform Advantages
The brand feature and core competitiveness of Tepmax lies in the in vivo pharmacological efficacy evaluation system for large animals, including monkeys, piglets, dogs and other animals.Currently the platform system has been constructed for atrial fibrillation, heart failure, spinal cord injury, epilepsy, asthma, systemic lupus erythematosus, psoriasis, atopic dermatitis, sepsis, pulmonary hypertension, pulmonary/hepatic/kidney fibrosis, hypertension, arthritis, pain, thrombosis, IgA nephropathy, Parkinson's disease, Alzheimer's disease, stroke, osteoporosis, muscular dystrophy, obesity, atherosclerosis, hyperlipidemia, diabetes, Diabetic nephropathy, diabetic ophthalmopathy, diabetic foot, fatty liver, NASH, and other disease models encompassing multiple systems/tissues. After market research, competitors' animal efficacy evaluation platforms are all very weak, engaged in the type of business homogenization of serious involution; while we focus on the research of differentiated large and small animal disease models, and insist on making our animal disease modeling business into a fine product, to form the expert level of the industry to empower the global customers' platform. With our unique large and small animal disease models and testing system with breadth and depth, as well as our outstanding scientific research team, we will form a crushing advantage in the competition of the same industry in the market.